



Physiological role of bicarbonate in microbes: A double-edged sword?

Ashok Aspatwar, Jenny Parkkinen & Seppo Parkkila

To cite this article: Ashok Aspatwar, Jenny Parkkinen & Seppo Parkkila (2025) Physiological role of bicarbonate in microbes: A double-edged sword?, *Virulence*, 16:1, 2474865, DOI: [10.1080/21505594.2025.2474865](https://doi.org/10.1080/21505594.2025.2474865)

To link to this article: <https://doi.org/10.1080/21505594.2025.2474865>



© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 06 Mar 2025.



Submit your article to this journal [↗](#)



Article views: 37



View related articles [↗](#)



View Crossmark data [↗](#)

Physiological role of bicarbonate in microbes: A double-edged sword?

Ashok Aspatwar^a, Jenny Parkkinen^a, and Seppo Parkkila ^{a,b}

^aFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ^bDepartment of Clinical Chemistry, Fimlab Laboratories PLC, Tampere University Hospital, Tampere, Finland

ABSTRACT


HCO_3^- is involved in pH homeostasis and plays a multifaceted role in human health. HCO_3^- has been recognized for its antimicrobial properties and is pivotal in bacterial antibiotic susceptibility. Notably, the interconversion between CO_2 and HCO_3^- , facilitated by the enzyme carbonic anhydrase (CA), is crucial in tissues infected by pathogens. Studies have highlighted the antimicrobial potency of CA inhibitors, emphasizing the importance of this enzyme in this area. The potential of HCO_3^- as an antibiotic adjuvant is evident; its ability to increase virulence in pathogens such as *Enterococcus faecalis* and *Mycobacterium tuberculosis* requires meticulous scrutiny. HCO_3^- modulates bacterial behaviours in diverse manners: it promotes *Escherichia coli* O157:H7 colonization in the human gut by altering specific gene expression and, with *Pseudomonas aeruginosa*, amplifies the effect of tobramycin on planktonic cells while promoting biofilm formation. These multifaceted effects necessitate profound mechanistic exploration before HCO_3^- can be considered a promising clinical adjuvant.

ARTICLE HISTORY

Received 9 December 2024
Revised 11 February 2025
Accepted 25 February 2025

KEYWORDS


Bicarbonate; virulence; antibacterial activity; antibiotics; biofilm; bacteria



Introduction

HCO_3^- plays a multifaceted role in both human health and disease. Serving as the primary pH buffer in mammals, it maintains the acid-base balance, which is essential for normal cellular function [1]. The stability of the body's pH is critical, and even minor deviations can lead to severe metabolic dysfunction [1]. HCO_3^-

production is a fascinating biochemical process. Carbon dioxide (CO_2), a byproduct of various metabolic processes, is present in the body and combines with water (H_2O). This reaction is catalysed by an enzyme known as carbonic anhydrase (CA), resulting in the formation of HCO_3^- and a proton (H^+). Given the importance of this reaction in pH regulation, the

CONTACT Ashok Aspatwar  ashok.aspatwar@tuni.fi

© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

widespread use of CA enzymes is unsurprising. Interestingly, bacteria that have evolved various physiological mechanisms in eggs possess multiple CA genes, emphasizing their importance [1]. Thus, the role of HCO_3^- extends beyond human physiology.

The pathogenic bacteria responsible for various infectious diseases have evolved to thrive in HCO_3^- -rich environments. This underlines the importance of HCO_3^- in understanding host-pathogen interactions [2]. The antibacterial and antifungal properties of HCO_3^- have been recognized for years [3]. Historically, research since the 1980s has highlighted its efficacy against periodontal pathogens, leading to its incorporation into dental hygiene products [4]. Over the years, its antimicrobial effects against a plethora of pathogens, such as *E. coli*, *Lactobacillus plantarum* (*L. plantarum*), *Staphylococcus aureus* (*S. aureus*), and *P. aeruginosa*, and even fungi, such as *Saccharomyces cerevisiae* (*S. cerevisiae*) and *Hansenula wingei* (*H. wingei*), have been documented [5]. However, the exact molecular mechanisms remain the subject of intensive research.

HCO_3^- modulates the pH gradient across bacterial membranes, affecting both gram-positive and gram-negative bacteria. Notably, HCO_3^- hinders biofilm formation by *P. aeruginosa*, a notorious pathogen, thereby hampering its virulence [6]. The enhancement of antibiotic potency by HCO_3^- is truly remarkable. In addition to enhancing the effects of traditional antibiotics, HCO_3^- increases the efficacy of antimicrobial peptides. Thus, it could be an adjunct to antibiotic treatment and should be considered when new antibacterial drugs are developed [7]. Although HCO_3^- enhances the efficacy of antibiotics, it also promotes the growth of certain pathogenic bacteria. For example, *M. tuberculosis*, the causative agent of tuberculosis, flourishes in macrophage compartments at various pH values. HCO_3^- contributes to the virulence of this pathogen [8]. Moreover, HCO_3^- positively influences the export of extracellular DNA in several non-tuberculous mycobacteria, an effect that is pH-independent [8,9]. Hence, the dual role of HCO_3^- as both a supporter and an inhibitor of bacterial growth necessitates a cautious approach when considering its therapeutic applications [9,10].

HCO_3^- has a complex role in bacterial interactions, enhancing antibiotic effectiveness and promoting virulence gene expression in various bacteria, including *B. anthracis* and *V. cholerae* [11]. Interestingly, CA inhibitors can inhibit this HCO_3^- -induced virulence. Furthermore, although HCO_3^- synergizes with tobramycin against *P. aeruginosa* in one context, it also promotes biofilm growth [12]. Given these contradictory findings, a nuanced understanding of the

molecular role of HCO_3^- is essential before its use as an antibiotic adjuvant. In conclusion, the roles of HCO_3^- in health, disease, and therapeutic applications are multifaceted. With a surge in HCO_3^- -related studies, the future promises more insights into its potential benefits and challenges.

Physiological role of HCO_3^- in health and diseases in humans

HCO_3^- is produced by the reversible hydration of CO_2 by CAs ($\text{CO}_2 + \text{H}_2\text{O} \rightleftharpoons \text{HCO}_3^- + \text{H}^+$); it is one of the major anions in humans, and the main function of HCO_3^- is pH homeostasis [1,13]. In addition to intracellular fluid, body secretions such as saliva, tears, aqueous humour, pancreatic juice, intestinal fluid, airway surface liquid (ASL), and cerebrospinal fluid contain different concentrations of HCO_3^- , which then controls the activity and stability of the proteins dissolved in these fluids [14]. Many epithelia specialize in HCO_3^- -rich fluid secretion, which generates flow, alters viscosity, controls pH, and potentially protects luminal and intracellular structures from chemical stress and infections. In hypertensive adults, a higher concentration of HCO_3^- is associated with better cognitive and executive performance than a lower concentration of HCO_3^- , suggesting that a low concentration of HCO_3^- is harmful to neuronal activity [15]. HCO_3^- plays an important role in the capacitation of sperm by alkalizing the sperm cytosol, which is needed for plasma membrane hyperpolarization and hyperactivation of motility and acts as a second messenger, triggering sperm hypermobility and the acrosomal reaction [16]. The transport of HCO_3^- through anion channels influences the membrane potential of epithelial cells. In the nervous system, HCO_3^- transport through ion channels, including glycine and GABA receptors, is needed for the regulation of neuronal excitability [14]. In mucosal epithelia, HCO_3^- promotes the solubilization and expansion of mucin molecules [14]. HCO_3^- has been shown to play a role in cardiac function in isolated cardiomyocytes, which show increased contractility [17].

Studies have shown that rhinoviruses and coronaviruses enter host cells via fusion with cellular membranes at low pH [18]. In SARS-CoV-2-infected patients, nasal irrigation and oral rinsing with 59.5 mM HCO_3^- solution cleared the virus [18]. It is believed that HCO_3^- increases the pH in vesicles/endosomes and inhibits the nucleocapsid release of SARS-CoV-2, which requires an acidic endosomal environment for uncoating. In addition, in people with flu, there was a decrease in the levels of HCO_3^- both in blood plasma

and in tissues, suggesting that proper regulation of HCO_3^- protects humans from infections.

Defects in either the production or transport of HCO_3^- lead to various diseases, including systemic acidosis, brain dysfunction, kidney stones, hyperammonaemia, hypertension, respiratory, gastrointestinal, and genitourinary system diseases, cystic fibrosis (CF), xerostomia, pancreatitis, and infertility [1,13,14]. HCO_3^- has been used for the treatment of sepsis, which is a life-threatening medical emergency, and CF [19]. HCO_3^- has been shown to improve the outcome of sepsis patients with acidosis [19]. Patients with renal tubular acidosis and diarrhoea are given HCO_3^- replacement therapy. When HCO_3^- is administered, it primarily increases plasma HCO_3^- levels, thus countering acidemia and helping restore the physiological pH balance [20]. The therapeutic effects of HCO_3^- administration are especially important in conditions such as metabolic acidosis, where there is an imbalance in the acid-base equilibrium [20]. However, HCO_3^- administration has several possible adverse effects. Some of these effects include an increased risk of hypokalemia, in which blood potassium levels become dangerously low [20]. There is also the possibility of inducing metabolic alkalosis, a condition in which there is a primary increase in serum HCO_3^- [20].

The potential physiological consequences of administered HCO_3^- might also include a sudden increase in haemoglobin-oxygen affinity through the Bohr effect, hypercapnia, and other related effects [21]. It has been shown that 89.3–100 mm HCO_3^- is safe for the human body and has no considerable side effects. Treatment with intravenous infusion of HCO_3^- leads to significant inhibition of lower respiratory tract pathogens such as bacteria, fungi, and mycobacteria. A cohort study regarding the oral rinse of sodium bicarbonate revealed a significant increase in salivary pH and prevented overgrowth of acid uric bacteria [22].

HCO_3^- and bacteria as foes: antimicrobial potential of HCO_3^- and its influence on other antimicrobial agents

Antifungal and antibacterial activity of HCO_3^-

HCO_3^- exhibits significant antibacterial and antifungal properties and can effectively inhibit the growth of *Streptococcus mutans*, especially when combined with sodium dodecyl sulphate [23]. A study on the antifungal activity of HCO_3^- involving 70 fungal strains isolated from skin and nail infections revealed that HCO_3^- (119.05 mm) could curb the growth of 80% of these pathogens. The effectiveness varies based on the type of fungi, with a minimum inhibitory concentration

(MIC₉₀) against yeast of 59.52 mm, dermatophytes requiring 238.10 mm, and moulds needing up to 476.19 mm [24]. Furthermore, when tested against clinical isolates, HCO_3^- (119.05 mm) completely stopped the growth of 19 out of 24 samples and notably reduced the growth of the remaining samples within a week compared with samples without HCO_3^- [24]. These findings suggest that HCO_3^- can be used in combination with other antifungal agents, particularly for skin fungal infections and onychomycosis.

A recent study on the antibacterial properties of HCO_3^- against *S. aureus*, *P. aeruginosa*, and *E. coli* has indicated its potential for the treatment of concomitant sepsis [25]. They reported a significant decrease in bacterial colonies within 24 h of HCO_3^- exposure. Given that HCO_3^- is already used to manage metabolic acidosis in intensive care units, these findings suggest that it may also offer antimicrobial benefits for patients with sepsis [25].

Recent studies have expanded our understanding of the antimicrobial and antibiofilm activities of HCO_3^- . It inhibits the growth and biofilm formation of various microbes, including *P. aeruginosa*, *Klebsiella pneumoniae* (*K. pneumoniae*), *Actinomyces naeslundii* (*A. naeslundii*), and *Candida albicans* (*C. albicans*). It also has a lethal effect on *Aspergillus parasiticus*, unrelated to pH or aflatoxin distribution [26]. HCO_3^- drastically reduced aerobic plate counts in tests against aerobic and anaerobic bacteria such as *E. coli*, *S. aureus*, and *P. aeruginosa*. A 1,000-fold reduction was observed at a 120 mm concentration. Even common yeasts such as *S. cerevisiae* and *H. wingei* are highly sensitive, with counts reduced 100,000-fold by 60 mm HCO_3^- [27].

Another study revealed that 1 M HCO_3^- significantly inhibited bacterial, fungal, and mycobacterial growth both *in vitro* and *in vivo*. In both experiments, compared with saline (negative control), HCO_3^- substantially reduced the number of colony-forming units for bacteria and fungi. Moreover, HCO_3^- was particularly effective against *M. tuberculosis*, resulting in a lower prevalence of acid-fast bacilli than saline in both settings [28]. These findings highlight the potential of HCO_3^- as an antimicrobial agent against a range of bacterial and fungal pathogens. Table 1 summarizes the antibacterial and antifungal activities of HCO_3^- .

HCO_3^- enhances antibacterial peptide activity

In human systems, the role of antimicrobial peptides (AMPs) as natural antibiotics, which often have no effect on microbes under culture conditions, remains largely elusive [7]. HCO_3^- plays a key role in enhancing the effectiveness of AMPs, such as cathelicidins and

Table 1. Antibacterial and antifungal activities of HCO_3^- .

Pathogen	Inhibition	Biofilm	Reference
<i>S. aureus</i>	+	+	[6,25,27],
<i>P. aeruginosa</i>	+	+	[6,25,27,29]
<i>E. coli</i>	+	–	[25,27]
<i>H. influenzae</i>	+	–	[29]
<i>B. cepacia</i>	+	–	[29]
<i>Prevotella intermedia</i>	+	–	[30]
<i>Streptococcus sanguinis</i>	+	–	[30]
<i>Aggregatibacter actinomycetemcomitans</i>	+	–	[4,30]
<i>Actinomyces viscosus</i>	+	–	[30]
<i>K. pneumoniae</i>	+	+	[26]
<i>A. naeslundii</i>	+	+	[26]
<i>Haemophilus aphrophilus</i> (<i>H. aphrophilus</i>)	+	–	[4]
<i>Eikenella corrodens</i> (<i>E. corrodens</i>)	+	–	[4]
<i>Capnocytophaga gingivalis</i> (<i>C. gingivalis</i>)	+	–	[4]
<i>M. tuberculosis</i>	+	–	[28]
<i>H. wingei</i>	+	–	[27]
<i>C. albicans</i>	+	+	[26]
<i>A. parasiticus</i>	+	–	[31]
<i>S. cerevisiae</i>	+	–	[24,27]

“+” indicates growth inhibition of the organism and inhibition of biofilm, whereas “–” indicates no growth inhibition or biofilm.

defensins [32,33]. To test the hypothesis that HCO_3^- enhances the effectiveness of AMPs, an *in vitro* study was conducted using animal cell cultures with HCO_3^- in the medium. A study revealed that pathogenic bacteria, such as *S. aureus* and *E. coli*, changed cell wall thickness and sigma factor B expression, increasing their susceptibility to the AMP LL-37. These findings suggest that HCO_3^- could act as a cofactor to increase the antimicrobial potency of AMPs, such as LL-37 [7]. Moreover, HCO_3^- enhances the antimicrobial activity of various structurally different AMPs, including murine cathelicidins (mCRAM), linear porcine cathelicidin (PR-39), and both β -murine and human defensins (Cryptdin-4 and HBD-2) [7]. These findings shed light on the interplay between HCO_3^- and AMPs and suggest that HCO_3^- can act as a cofactor to increase the antimicrobial potency of AMPs.

HCO_3^- is a crucial component of the buffering system in the human body and has a broad-spectrum antimicrobial effect. It also amplifies the antibacterial activity of other innate immune elements. A previous study investigated the effects of physiological concentrations of HCO_3^- (25 mM) on various innate immunity mediators, including defensins and cathelicidins [34]. A previous study revealed that HCO_3^- enhanced the antimicrobial activities of α -defensin, LL-37, indolicidin, bactenesin, and leukocyte protegrin against *E. coli* and *S. aureus* [34].

Moreover, many innate immune system components can disrupt the bacterial membrane potential. This suggests that the host uses a coordinated approach to target bacterial PMF in an HCO_3^- -rich environment [35]. Thus, HCO_3^- possesses intrinsic antibacterial properties and is vital for boosting the immune response. It synergizes with the body's physical and

chemical defences to effectively eliminate infection-causing pathogens [35].

Effect of HCO_3^- on other antimicrobial compounds

Innovative antibacterial drug screening methods that mimic the host environment where bacteria reside continue to emerge [36]. Recent advances involve chemicals specifically designed to inhibit bacterial growth under conditions that closely mimic those within the host [35]. HCO_3^- is a chemical that is gaining attention for its ability to augment the activity of antimicrobial agents [37]. For example, a previous study demonstrated a significant synergistic effect when HCO_3^- (5 mM) was combined with kanamycin (3.12 $\mu\text{g/mL}$), resulting in an 80% (w/v) reduction in *E. coli* growth. In contrast, when used alone, HCO_3^- and kanamycin reduce *E. coli* growth by only 5% (w/v) and 15% (w/v), respectively [37]. Interestingly, HCO_3^- also displayed paradoxical eagle-like behaviour at concentrations greater than 20 mM. Further studies are needed to understand its variable interactions with antibiotics, as antibiotic activity is enhanced and suppressed depending on antibiotic concentration [37].

Studies with 25 mM HCO_3^- revealed its ability to increase the efficacy of eight antibiotic classes against both gram-positive and gram-negative bacteria [35]. Specific antibiotics, such as fluoroquinolones, tetracyclines, fosfomycin, and novobiocin, showed variable responses depending on the HCO_3^- concentration. This synergistic activity was not pH dependent but was rooted in the chemical properties of HCO_3^- .

One study reported that HCO_3^- disrupts the proton motive force (PMF) in bacterial cells, thereby affecting antibiotic effectiveness. The PMF, which is crucial for bacterial energy production, consists of an electrical

potential ($\Delta\psi$) and a proton gradient (ΔpH) [38]. The influence of HCO_3^- varies depending on the antibiotic and its reliance on the PMF components. For example, it suppresses the use of tetracyclines, which rely on the ΔpH , while enhancing the use of aminoglycosides, which depend on the $\Delta\psi$ [39,40]. This suggests that HCO_3^- modulates antibiotic uptake by altering PMF components, with effects extending to fluoroquinolones, depending on the specific conditions (Table 2) [35].

Figure 1 illustrates a hypothetical model that shows the influence of HCO_3^- on antibiotics with different physico-chemical properties. HCO_3^- is a constituent of the medium ΔpH , representing the acidic extracellular environment and contributing to the PMF across the cytoplasmic membrane in gram-negative and gram-positive bacterial species. Aminoglycosides with a positive charge utilize the negative interior component of the membrane potential ($\Delta\psi$) for transportation [35].

One study explored through transcriptional analysis how HCO_3^- enhances the efficacy of aminoglycosides in *E. coli* [37,43]. In this study, HCO_3^- (40 mM) treatment for 40 min during the logarithmic growth phase reduced the growth of viable *E. coli*. Using RNA-seq analysis, the study revealed that HCO_3^- significantly altered gene expression, resulting in a tenfold increase in the expression of *tnaA*, which encodes tryptophanase, an enzyme crucial for tryptophan degradation.

These results imply that HCO_3^- could influence bacterial metabolism and susceptibility to antibiotics, although the specific mechanism remains unclear. This study highlights the complex interactions between HCO_3^- and bacterial growth. Elevated expression of *tnaA*, which leads to increased indole production, was found to work synergistically with HCO_3^- to inhibit the growth of *E. coli*. These findings suggest a potential role for indoles in growth inhibition. Moreover, HCO_3^- led to significant changes in iron metabolism, as indicated by the upregulation of genes related to iron acquisition and the downregulation of genes related to iron – sulphur proteins. These findings suggest that HCO_3^- -induced growth inhibition may be partially due to iron deficiency [37,43]. In another study, HCO_3^- was found to have varying effects on the effectiveness of fluoroquinolone antibiotics (Table 2) [41]. Specifically, it prevents the intracellular accumulation of delafloxacin, reducing its efficacy against multidrug-resistant *S. aureus* and *P. aeruginosa*.

Interestingly, HCO_3^- also exhibited dual behaviour with tobramycin, first showing increased antibiotic efficacy against planktonic *P. aeruginosa* but having an antagonistic effect that encouraged biofilm growth. These findings highlight the nuanced roles that HCO_3^- can play in modulating antibiotic activity and underscore the importance of understanding these interactions for more effective treatment strategies [12].

Table 2. Effect of HCO_3^- on antibiotic activity.

Antibiotic	Activity of HCO_3^-	Reference
Gentamicin, kanamycin, fluoroquinolones, macrolides aminoglycosides, polymyxin B, tobramycin β -lactam, cefazolin (CFZ), and oxacillin (OXA)	Synergistic	[12,37,41,42]
Tetracyclines, fosfomycin, novobiocin, some fluoroquinolones such as delafloxacin, kanamycin, gentamicin, nigericin, tobramycin	Antagonistic	[12,35,41]

^a HCO_3^- concentration >20 mM had an antagonistic effect on kanamycin.




Figure 1. A model depicts the effect of HCO_3^- on various classes of antibiotics. Credit: created via BioRender.com.

The increasing threat of antibiotic-resistant bacteria necessitates a comprehensive and globally coordinated response to ensure the continued efficacy of antibiotic treatments. The reliance of the healthcare industry on a single type of laboratory test for antibiotic susceptibility is a significant shortcoming, especially given that this test often does not replicate the complex interplay between hosts and pathogens in a living system. Emerging research has highlighted the limitations of standard antimicrobial susceptibility testing (AST) conducted in laboratory-specific media, which can produce misleading results. Some antibiotics that have proven ineffective in standard tests are highly effective in media that mimic host conditions. Conversely, certain antibiotics that pass conventional AST have demonstrated poor performance in living organisms.

A promising avenue for improving AST predictive accuracy involves incorporating HCO_3^- into the test medium. HCO_3^- , a common molecule in biological systems, triggers far-reaching changes in bacterial physiology and gene expression. By better simulating *in vivo* conditions, this modification enhances the ability of the test to identify effective treatments, thereby streamlining the development and prescription of antibiotics. The incorporation of HCO_3^- and other host-specific conditions into AST protocols could revolutionize the approach to combat antibiotic-resistant bacteria. By moving towards a more nuanced and biologically accurate model of infection, these advancements could lead to more targeted and effective

therapies, reducing the risk of antibiotic resistance and improving patient outcomes [44].

HCO_3^- sensitizes MRSA to β -lactams by regulating gene expression

There are two types of methicillin-resistant *S. aureus* (MRSA): one is susceptible to β -lactams, such as oxacillin and cefazolin, in the presence of HCO_3^- , whereas the other is not [45]. The effect of HCO_3^- on susceptibility is multifaceted: it alters PMF and downregulates key resistance genes, *mecA*, and *sarA*, in responsive strains [35,45,46]. Studies indicate that HCO_3^- in culture media enhances the susceptibility of specific MRSA strains to β -lactams, such as cefazolin and oxacillin. Enhanced susceptibility was also observed in *ex vivo* endocarditis models, where HCO_3^- sensitizes MRSA strains to β -lactams. This effect varies depending on the genetic background of the strain [42,45–47].

HCO_3^- exposure modulates gene expression in MRSA strains, affecting key genes, such as *mecA*, *blaZ*, *pbp4*, *vraSR*, *prfA*, *sigB*, and *floA*, which are critical for alternative penicillin-binding protein (PBP2a) production and maturation and membrane PBP2a and PrfA protein content. Specifically, it significantly downregulated *mecA*, *blaZ*, the *vraSR-prfA* gene axis, *pbp4*, and carotenoids (Figure 2) while upregulating *floA* across all MRSA strains [46].

These findings revealed that HCO_3^- modulates a set of genes essential for the HCO_3^- -responsive MRSA




Figure 2. The model illustrates the effects of HCO_3^- on PBP2 and peptidoglycan biosynthesis. HCO_3^- -responsive strains display effects such as decreased production of the PBP2a protein, reduced expression of *pbp4* and *vraSR*, and lower levels of *PrfA*. Moreover, HCO_3^- inhibits carotenoid production and increases *floA* expression, leading to unstable functional membrane microdomains (FMMs) [46]. Credit: created via BioRender.com.

phenotype via PBP2a function and maturation [46]. Another study revealed that HCO_3^- -responsive MRSA isolates are susceptible to CFZ and OXA, and genotypic markers such as clonal complex 8 [CC8], *agr* I, and *spa* t008 are associated with HCO_3^- responsiveness of HCO_3^- to OXA [42]. RNA-Seq identified key genes that were differentially expressed in HCO_3^- -responsive strains, including those in the *sigB-sarA-agr* axis, cell wall-associated genes, and those related to autolysis (Table 3) [46]. Studies with a fluorescent penicillin probe (bocillin-FL) suggested that HCO_3^- affects β -lactam binding to both the cell surface and PBP2a, indicating the responsiveness of MRSA to β -lactams [47].

Recent research revealed that HCO_3^- decreases wall teichoic acid (WTA) levels and molecular weights in

HCO_3^- -responsive MRSA strains. It also induces increased autolysis and irregular cell division, both of which are associated with the disruption of WTA synthesis. These data suggest that HCO_3^- inhibits WTA biosynthesis via a posttranslational mechanism involving specific genes such as *tarO*, *tarG*, *dltA*, and *fntA* (Figure 3). This study revealed that HCO_3^- directly influences WTA biosynthesis in HCO_3^- -responsive MRSA strains [50].

Figure 3 shows the pathways involved in the synthesis and maturation of PG and WTA, underscoring the role of HCO_3^- in affecting these processes and contributing to the β -lactam- and HCO_3^- -responsive phenotype. This study confirms the inhibitory effect of HCO_3^- on WTA production, which is linked to the increased susceptibility of MRSA to β -lactam

Table 3. Regulation of genes by HCO_3^- and susceptibility to β -lactams.

Regulated genes	Pathogen	Pathway effected	Reference
<i>mecA</i> and <i>sarA</i>	MRSA HCO_3^- -responsive	Production/maturation of PBP2a and PrsA protein	[42]
<i>crtM</i> , <i>sigB</i> , <i>sarA</i> , <i>agrA</i> , <i>hla</i> , <i>fntA</i> , and <i>icaA</i>	<i>S. aureus</i>	Regulation of virulence factors	[48]
<i>mecA</i> and <i>blaZ</i> , <i>vraSR-prsA</i> gene axis, and <i>pbp4</i> .	MRSA HCO_3^- -responsive	Production/maturation of PBP2a,	[49]
<i>sigB-sarA-agr</i> regulon <i>cap8</i> , <i>clpL</i> , <i>sasD</i> , <i>aaa</i> , <i>vra</i> , <i>XkdABCDF</i> , <i>betAB</i> , <i>icaR</i> , <i>rsp</i> , <i>clfA</i> , <i>clfB</i> , <i>agr</i> , <i>sdrH</i> , <i>fntA</i> , <i>fntB</i> , <i>atl</i> , <i>sceD</i> , <i>isaA</i> , <i>fntA</i> , <i>ddh</i> , <i>pbp2</i> , <i>bccT</i> , <i>usp</i>	MRSA HCO_3^- -responsive and nonresponsive	Virulence autolysins cell wall synthesis, osmotic stress response,	[46]




Figure 3. The model elucidates the impact of HCO_3^- on the synthesis of WTA and the susceptibility of strains responsive to β -lactams [50]. Credit: created via BioRender.com.

antibiotics [50]. Another study revealed that HCO_3^- enhances the efficacy of antibacterial drugs against *S. aureus* both *in vitro* and *in vivo*, reducing the production of virulence factors and increasing susceptibility to oxidative stress [48].

HCO_3^- and bacteria as friends: regulation of virulence genes in pathogenic strains

Effect of HCO_3^- on virulence expression in *E. coli*

Enterohemorrhagic *E. coli* (EHEC), known for causing bloody diarrhoea and haemolytic uraemic syndrome, adheres to the intestinal mucosa and creates attaching and effacing (A/E) lesions via the locus for enterocyte effacement (LEE) genes. Studies have shown that HCO_3^- in the medium increases bacterial adherence and the expression of LEE-encoded genes, such as *intimin*, *Tir*, *EspA*, and *EspB* [51]. Furthermore, the expression of *ler*, a crucial regulator of LEE-encoded genes, depends on the HCO_3^- concentration in the medium. This suggests that HCO_3^- acts as an intestinal signalling molecule, facilitating EHEC colonization, particularly in the lower intestine, where the HCO_3^- concentration is relatively high [51].

Another study has shown that HCO_3^- is crucial for activating the *rscDB* and *rscB* genes. An intact Rcs system and *grvA* activator are also vital for LEE stimulation, highlighting the role of HCO_3^- in the virulence of intestinal pathogens [52]. Notably, *RcsB* activates and represses LEE transcription and requires HCO_3^- for activation [53]. Both *rscB* and *GrvA* are essential for

this HCO_3^- -induced activation [52]. *GrvA* and *RcsB* jointly mediate the role of HCO_3^- in activating the LEE pathway, which is critical for intestinal pathogen colonization (Figure 4).

Effect of HCO_3^- on virulence expression in *Vibrio cholerae*

V. cholerae, a gram-negative bacterium, causes cholera, which is characterized by severe diarrhoea. The pathogen has two primary biotypes, classical and El Tor, each with unique *in vitro* growth conditions for virulence gene expression [54]. When exposed to specific triggers or upon infection, *V. cholerae* initiates a complex regulatory cascade. This leads to the production of the regulatory protein ToxT, which activates the transcription of key virulence genes, including those encoding cholera toxin (CT), toxin-coregulated pilus (TCP), and other important virulence genes [11].

Studies have shown that HCO_3^- stimulates CT expression in the *V. cholerae* El Tor biotype and enhances ToxT activity, a key regulatory protein for virulence genes [11]. Both the classical and El Tor biotypes showed inactive ToxT in experiments without HCO_3^- . However, adding HCO_3^- significantly upregulated CT and TCP expression in both biotypes without altering ToxT production levels. The presence of ethoxzolamide, a CA inhibitor, disrupted this HCO_3^- -mediated virulence induction, suggesting the role of CO_2 to HCO_3^- conversion by CA in enhancing virulence [11]. HCO_3^- is a key chemical trigger for




Figure 4. The model explains the GrvA-dependent regulation of acid resistance (GDAR) and LEE-dependent adherence by *E. coli*. Credit: created via BioRender.com.

virulence gene activation, as *V. cholerae* colonizes the HCO_3^- -rich upper small intestine (Figure 5) [55].

Effect of HCO_3^- on virulence expression in *Bacillus cereus* and *Bacillus anthracis*

Bacillus cereus (*B. cereus*) is a gram-positive, rod-shaped foodborne pathogen responsible for gastrointestinal symptoms and potentially fatal lower respiratory infections, even with antibiotic treatment [56,57]. Another member of this bacterial group, *Bacillus anthracis* (*B. anthracis*), is known to cause anthrax and is considered a bioterrorism agent because of its lethal nature and the plasmids p \times O1 and p \times O2 [58].

HCO_3^- and CO_2 , which are essential for pH regulation in the body, increase the expression of genes associated with anthrax toxin components [59]. These components make the environment in mammalian hosts conducive to pathogenic bacteria that thrive in HCO_3^- -rich settings. Indeed, both CO_2 and HCO_3^- are vital to host-pathogen dynamics, especially in *B. anthracis* [2,60].

The virulence plasmid p \times O1 harbors genes for significant anthrax toxins and poly γ -d-glutamic acid capsule (PGA), a key virulence factor [61,62]. PGA transcription is increased by $\text{CO}_2/\text{HCO}_3^-$ through positive regulation of the capsule biosynthetic operon capBCAD and the plasmid regulators *atxA*, *acpA*, and *acpB* [63]. *In vitro*

studies have demonstrated that genes controlled by *atxA*, *acpA*, and *acpB* are induced by HCO_3^- [59,64,65]. A study has shown that in *atxA* 1 strains, elevated $\text{CO}_2/\text{HCO}_3^-$ and temperature increase the expression of toxin genes, namely, *pag*, *lef*, and *cya* [61]. Interestingly, $\text{CO}_2/\text{HCO}_3^-$ and temperature combined bolster toxin gene expression, with a sixfold increase in *atxA* mRNA expression at 37°C compared with that at 28°C [59]. These findings indicate that HCO_3^- and temperature jointly regulate the expression of the three *B. anthracis* toxin genes in a coordinated manner [59].

Another study comparing the gene expression profiles of *B. cereus* strain G9241 and an attenuated *B. anthracis* (Sterne 34F 2) strain in high $\text{CO}_2/\text{HCO}_3^-$ (1666.67 mm) environments versus ambient air identified marked differences in gene expression in the presence of $\text{CO}_2/\text{HCO}_3^-$ [66,67]. Intriguingly, gene expression in the G9241 strain differs from that in *B. anthracis*, possibly because it is regulated by PlcR and anthrax toxin activator (AtxA) transcriptional regulators [66,67].

Effect of HCO_3^- on virulence in *Citrobacter rodentium* and *E. faecalis*

C. rodentium is a gram-negative bacterium that predominantly infects mouse intestines and occasionally acts as an opportunistic pathogen in humans [68].




Figure 5. The model illustrates the expression of virulence genes by HCO_3^- . *V. cholerae* strains carrying inactive ToxT protein enter the upper small intestine (left). The HCO_3^- in the intestinal lumen (center), ToxT, activates TCP production. In the mucus layer, higher HCO_3^- levels (right) induce virulence genes and subsequent CT production. Credit: created via BioRender.com.

A study focusing on how a SlyS-like regulator interacts with environmental factors, particularly HCO_3^- , revealed that HCO_3^- activates the transcription of the *adcA* and *kfc* genes. These genes are essential for bacterial adhesion and colonization. This study revealed that HCO_3^- triggers the transcription of these genes and enhances the binding affinity of RegA for its target DNA [2]. These findings highlight the significant role of HCO_3^- in modulating bacterial virulence gene expression, potentially offering new avenues for understanding bacterial colonization and infection processes.

Antibiotic-resistant *E. faecalis* can cause urinary tract infections (UTIs), which present healthcare challenges. In *E. faecalis*, the gene *EbpR*, a member of the *AtxA/Mga* regulator family, influences biofilm development by increasing the expression of the endocarditis and biofilm-associated pilus operon (*ebpABC*) [69,70]. A study showed that treating *E. faecalis* with 100 mM HCO_3^- upregulated *EbpR* and related genes and enhanced pili production and biofilm formation [69]. Research has revealed 73 HCO_3^- -responsive genes that are linked mainly to transport systems, indicating that HCO_3^- modulates virulence in *E. faecalis* in a manner similar to its effects on other pathogens, such as *V. cholerae*, *B. anthracis*, *C. neoformans*, and *C. rodentium* [2,55,63,71,72].

Role of HCO_3^- in mycobacterial virulence gene expression

In nontuberculous mycobacteria (NTMs), HCO_3^- has been shown to influence the export of extracellular DNA (eDNA), which is crucial for antibiotic resistance and biofilm formation, and this influence is independent of pH (Table 4) [73]. Interestingly, in *M. avium*, inactivation of CAs diminishes the transport of eDNA, whereas re-establishment of CA activity restores eDNA transport. This highlights the significant role of CAs in the release of eDNA and biofilm formation [73]. Ethoxzolamide (ETZ), a potent CA inhibitor, significantly impairs eDNA export, suggesting that CA plays a role via HCO_3^- [8,75].

In addition, in *M. tuberculosis*, ETZ disrupts the PhoPR signalling pathway, resulting in changes similar to those observed in PhoPR mutants, such as down-regulation of the PhoPR regulon, reduction in virulence-associated lipids, and inhibition of Esx-1 protein secretion (Table 4) [74]. This highlights a different aspect of the role of HCO_3^- in bacterial physiology, contrasting its inhibition of gram-positive and gram-negative bacteria, including *M. tuberculosis*.

Bicarbonate and CO_2 as mediators of host immunity and the regulation of pathogenicity

HCO_3^- is the second most abundant anion in the human body; in addition to its role in pH regulation, it controls the activity of many proteins in the body, including immune components [14]. In cystic fibrosis (CF), CF transmembrane regulator (CFTR), an ATP binding cassette, is required for HCO_3^- secretion, and a mutation in CFTR leads to a defect in this anion in the CF lung. The bacteria found in CF are *S. aureus*, *H. influenzae* and *P. aeruginosa*, in which the host immune system responds via leukocytes and other immune components, including AMPs [76]. It has been demonstrated that the use of HCO_3^- enhances this immune response to combat these pathogens in CFs both *ex vivo* and *in vivo* [76]. Furthermore, when combined with vaccines, HCO_3^- significantly increases the immune response in poultry, suggesting its importance in the immunity of the host [77]. In mice, inoculation of a vaccine with HCO_3^- significantly enhances the protective immune response against *Brucella* compared with that of a formulation without HCO_3^- [78].

An increase in CO_2 or hypercapnia in multiple inflammatory diseases is known to suppress immune cell activity [79]. It has also been shown that bacterial infections and hypercapnic acidosis impair immune cell function, leading to immunosuppression and increased patient mortality after pneumonia [79,80]. A recent study demonstrated that elevated CO_2 reduces monocyte and macrophage migration via inflammatory gene expression and decreases the intracellular pH, which is also dependent on the activity of CA, suggesting that

Table 4. Regulation of genes by HCO_3^- and pathways in pathogenic bacteria.

Pathogen	Genes/Component	Effect	Reference
<i>E. coli</i>	<i>rcsDB</i> , <i>rcsB</i> , <i>ler</i> , <i>Tir</i> , <i>EspA</i> , and <i>EspB</i>	Toxin secretion and virulence	[51–53]
<i>V. cholerae</i>	CT, ToxT, TCP, <i>pag</i> , <i>lef</i> , and <i>cya</i>	Toxin secretion and virulence	[11]
<i>B. anthracis</i>	PGA capsule, <i>capBCAD</i> , <i>atxA</i> , <i>acpA</i> , <i>acpB</i> , <i>pag</i> , <i>lef</i> , and <i>cya</i>	Virulence, toxins	[11,61–63,71]
<i>C. neoformans</i>	Cac1adenylyl cyclase	Capsule synthesis	[72]
<i>E. faecalis</i>	<i>ebpR</i> , <i>ebpABC</i>	Virulence, biofilm	[69,70]
<i>C. rodentium</i>	<i>adcA</i> , <i>kfc</i> , <i>RegA</i>	Virulence	[2]
<i>M. avium</i>	eDNA	Biofilm formation	[73]
<i>M. tuberculosis</i>	Esx-1	Virulence	[74]

CO₂ immunomodulates immune cells through a CA2-coupled change in the intracellular pH [79]. In mice, increased CO₂ altered the immune response to inflammatory agents such as lipopolysaccharide (LPS) and organic dust [81]. Recent studies carried out in mycobacteria revealed that high levels of CO₂ induce PhoPR signalling, which is independent of pH, suggesting that the PhoPR regulon functions as a CO₂ sensor. Interestingly, the CA inhibitor ethoxzolamide (ETZ) inhibited PhoPR signalling, supporting the hypothesis that CO₂ plays a role in regulating PhoPR. Knockdown of CA resulted in a reduction in virulence. Transcriptional profiling studies at 5% CO₂ revealed the induction of PhoPR regulon genes, which include the ESX-1 secretion system [82].

CAs and their inhibition in bacteria as an antimicrobial approach

Pathogenic microbes have become resistant to clinically used drugs, and novel antimicrobial compounds that target novel pathways of these pathogens are needed [83,84]. In the recent past, sequencing the genomes of pathogenic microbes revealed many alternate pathways that are crucial for their life cycle and can be targeted via novel antimicrobials devoid of resistance [84]. Among the alternative pathways associated with these pathogens, carbonic anhydrases play crucial roles and have been used as targets for the development of antimicrobial agents via small-molecule inhibitors. Pathogenic organisms contain both α -CAs and β -CAs that have been cloned, and studies have shown that CAs play crucial roles in the survival and pathogenesis of pathogens [85].

Pathogens sense CO₂ in their environment via HCO₃[−], which is generated by the enzymatic activity of CAs and regulates the expression of genes required for the virulence of these microbes [84]. In addition, studies have demonstrated that CAs are involved in many other functions, such as biofilm formation and survival in the host environment. In *E. faecalis*, disruption of α -CA sensitized bacteria to killing with gentamicin [86]. In *P. aeruginosa*, β -CA is required for calcium deposition and contributes to virulence [4]. The inactivation and inhibition of the activity of this CA chemical inhibitor reduced calcium deposition in this bacterium [73]. In mycobacterial species, CAs are required to transport eDNA, a component of biofilms, and to express virulence factors. Inhibition via EZA or inactivation of CA has been shown to reduce biofilm formation and attenuate virulence [8,9,73,74]. The inhibition of β -CAs with a specific inhibitor significantly reduced the bacterial load *in vivo* in zebrafish larvae

[75]. In addition, in *in vivo* studies involving *Neisseria* spp., *H. pylori*, *B. suis*, and *S. pneumoniae*, the growth of these pathogens could be impaired via the use of CA inhibitors [87]. *H. pylori* encounter bicarbonate, urea and acid in gastric environment. Analysis of *H. pylori* mutants showed that CAs play a role in maintaining activity of urease and acid resistance through HCO₃[−] in an acidic environment, suggesting the requirement of CAs for the bacterium for survival in the gastric niche [88].

The crystal structures of many microbial CAs have been resolved, and inhibition studies using different classes of inhibitors have been performed [85]. The CA inhibitors sulphonamides, dithiocarbamates, and inorganic anions have been shown to inhibit the α - and β -CAs of bacteria and fungi. Among CA inhibitors, sulphonamides/sulfamates represent one of the main classes of CAIs [89]. These compounds are already in clinical use for the treatment of various diseases, including acetazolamide, methazolamide, and ethoxzolamide, which inhibit all CAs, including CAs, from pathogenic microbes. Sulphonamides/sulfamates/sulamides have been shown to inhibit CAs both *in vitro* and *in vivo* in mice infected with antibiotic-resistant strains, confirming their role in contrasting bacterial antibiotic resistance [90]. In addition, phenol inhibitors, either alone or in combination with clinically used antibiotics, inhibit the growth of the bacterium and biofilm formation [87]. Both *in vitro* and *in vivo* inhibition studies have shown that the CAs of these pathogens can be novel targets for combating microbial infections that are devoid of resistance [8,9,75,91,92].

Concluding remarks

HCO₃[−] plays a pivotal role in human health and disease, and its role in cellular physiology involves pH regulation, suggesting its impact on various metabolic and signalling pathways. In the realm of microbial studies, HCO₃[−] has emerged as an agent of interest owing to its importance not only in microbial physiology but also in human physiology. The antimicrobial effects of HCO₃[−] are manifested in diverse ways, first by inhibition of the growth of pathogenic bacteria directly and second by increasing the effects of different antibiotics on pathogenic bacteria.

However, HCO₃[−] is a double-edged sword, as HCO₃[−] also regulates genes and increases virulence in certain pathogenic bacteria. This underlines the need for caution before integrating HCO₃[−] into clinical applications that target bacterial infections. As researchers dive deeper, the dichotomous nature of the effects of HCO₃[−], both inhibitory and promotional,

on bacterial virulence becomes evident. The path ahead necessitates a thorough and nuanced understanding of HCO_3^- before its widespread adoption in microbial therapies.

Acknowledgements

The authors thank the Finnish Cultural Foundation, Tampere Tuberculosis Foundation, Academy of Finland, and Jane and Aatos Erkko Foundation for their financial support for this study.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The work was supported by the Jane ja Aatos Erkon Säätiö Tampereen Tuberkuloosisäätiö.

Author contributions

Ashok Aspatwar: Conceptualization, preparing the original draft, preparing figures, and visualization; **Jenny Parkkinen:** Writing-reviewing and editing; **Seppo Parkkila:** Writing of the manuscript, reviewing and editing, supervision and financial support.

Author contributions

Original idea and original manuscript draft preparation: A.A. Data collection: A.A., review, writing, and editing: A.A., J.P., and S.P., Funding acquisition: A.A. (grants from the Finnish Cultural Foundation, Tampere Tuberculosis Foundation), S. P. (grants from the Academy of Finland, Jane and Aatos Erkko Foundation). Final approval: All the authors (A.A., J. P., and S.P.) read, agreed upon, and approved the final version of the manuscript for publication.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.

ORCID

Seppo Parkkila  <http://orcid.org/0000-0001-7323-8536>

References

- [1] Aspatwar A, Tolvanen MEE, Barker H, et al. Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiology. *Physiol Rev.* 2022;102(3):1327–1383. doi: [10.1152/physrev.00018.2021](https://doi.org/10.1152/physrev.00018.2021)
- [2] Yang J, Hart E, Tauschek M, et al. Bicarbonate-mediated transcriptional activation of divergent operons by the virulence regulatory protein, RegA, from *Citrobacter rodentium*. *Mol Microbiol.* 2008;68(2):314–327. doi: [10.1111/j.1365-2958.2008.06171.x](https://doi.org/10.1111/j.1365-2958.2008.06171.x)
- [3] Griffiths E, Humphreys J. Bacteriostatic effect of human milk and bovine colostrum on *Escherichia coli*: importance of bicarbonate. *Infect Immun.* 1977;15(2):396–401. doi: [10.1128/iai.15.2.396-401.1977](https://doi.org/10.1128/iai.15.2.396-401.1977)
- [4] Miyasaka KT, Genco RJ, Wilson ME. Antimicrobial properties of hydrogen peroxide and sodium bicarbonate individually and in combination against selected oral, gram-negative, facultative bacteria. *J Dent Res.* 1986;65(9):1142–1148. doi: [10.1177/00220345860650090601](https://doi.org/10.1177/00220345860650090601)
- [5] Corral LG, Post LS, Montville TJ. Antimicrobial activity of sodium bicarbonate. *J Food Sci.* 1988;53(3):981–982. doi: [10.1111/j.1365-2621.1988.tb09005.x](https://doi.org/10.1111/j.1365-2621.1988.tb09005.x)
- [6] Dobay O, Laub K, Stercz B, et al. Bicarbonate inhibits bacterial growth and biofilm formation of prevalent cystic fibrosis pathogens. *Front Microbiol.* 2018;9:2245. doi: [10.3389/fmicb.2018.02245](https://doi.org/10.3389/fmicb.2018.02245)
- [7] Dorschner RA, Lopez-Garcia B, Peschel A, et al. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. *FASEB J.* 2006;20(1):35–42. doi: [10.1096/fj.05-4406com](https://doi.org/10.1096/fj.05-4406com)
- [8] Aspatwar A, Kairys V, Rala S, et al. Mycobacterium tuberculosis β -carbonic anhydrases: novel targets for developing antituberculosis drugs. *Int J Mol Sci.* 2019;20(20):20(20. doi: [10.3390/ijms20205153](https://doi.org/10.3390/ijms20205153)
- [9] Aspatwar A, Winum J-Y, Carta F, et al. Carbonic anhydrase inhibitors as novel drugs against mycobacterial β -carbonic anhydrases: an update on in vitro and in vivo studies. *Molecules.* 2018;23(11):2911. doi: [10.3390/molecules23112911](https://doi.org/10.3390/molecules23112911)
- [10] Jones RT, Talley RS. Effects of gaseous CO_2 and bicarbonate on the growth of *Neisseria gonorrhoeae*. *J Clin Microbiol.* 1977;5(4):427–432. doi: [10.1128/jcm.5.4.427-432.1977](https://doi.org/10.1128/jcm.5.4.427-432.1977)
- [11] Abuaitha BH, Withey JH. Bicarbonate induces vibrio cholerae virulence gene expression by enhancing ToxT activity. *Infect Immun.* 2009;77(9):4111–4120. doi: [10.1128/IAI.00409-09](https://doi.org/10.1128/IAI.00409-09)
- [12] Kaushik KS, Stolhandske J, Shindell O, et al. Tobramycin and bicarbonate synergise to kill planktonic *Pseudomonas aeruginosa*, but antagonise to promote biofilm survival. *NPJ Biofilms Microbiomes.* 2016;2(1):16006. doi: [10.1038/npjbiofilms.2016.6](https://doi.org/10.1038/npjbiofilms.2016.6)
- [13] Aspatwar A, Supuran CT, Waheed A, et al. Mitochondrial carbonic anhydrase VA and VB: properties and roles in health and disease. *J Physiol.* 2023;601(2):257–274. doi: [10.1113/JP283579](https://doi.org/10.1113/JP283579)
- [14] Shin DH, Kim M, Kim Y, et al. Bicarbonate permeation through anion channels: its role in health and disease. *Pflügers Arch - Eur J Physiol.* 2020;472(8):1003–1018. doi: [10.1007/s00424-020-02425-x](https://doi.org/10.1007/s00424-020-02425-x)
- [15] Dobre M, Gaussoin SA, Bates JT, et al. Serum bicarbonate concentration and cognitive function in hypertensive adults. *Clin J Am Soc Nephrol.* 2018;13(4):596–603. doi: [10.2215/CJN.07050717](https://doi.org/10.2215/CJN.07050717)
- [16] Delgado-Bermúdez A, Yeste M, Bonet S, et al. A review on the role of bicarbonate and proton transporters during sperm capacitation in mammals. *Int J Mol Sci.* 2022;23(11):23(11. doi: [10.3390/ijms23116333](https://doi.org/10.3390/ijms23116333)

- [17] Wang HS, Chen, Y., Vairamani, K. and Shull, G.E., Critical role of bicarbonate and bicarbonate transporters in cardiac function. *World J Biol Chem.* **2014**;5 (3):334–345. doi: [10.4331/wjbc.v5.i3.334](https://doi.org/10.4331/wjbc.v5.i3.334)
- [18] Wang T, Zhang Y, Zhang R, et al. Efficacy of nasal irrigation and oral rinse with sodium bicarbonate solution on virus clearance for COVID-19 patients. *Front Public Health.* **2023**;11:1145669. doi: [10.3389/fpubh.2023.1145669](https://doi.org/10.3389/fpubh.2023.1145669)
- [19] Velissaris D, Karamouzou V, Ktenopoulos N, et al. The use of sodium bicarbonate in the treatment of acidosis in sepsis: a literature update on a long Term debate. *Crit Care Res Pract.* **2015**;2015:1–7. doi: [10.1155/2015/605830](https://doi.org/10.1155/2015/605830)
- [20] Tanios BY, Omran MO, Noujeim C, et al. Carbonic anhydrase inhibitors in patients with respiratory failure and metabolic alkalosis: a systematic review and meta-analysis of randomized controlled trials. *Crit Care.* **2018**;22(1):275. doi: [10.1186/s13054-018-2207-6](https://doi.org/10.1186/s13054-018-2207-6)
- [21] Coppola S, Caccioppola A, Froio S, et al. Sodium bicarbonate in different critically ill conditions: from physiology to clinical practice. *Anesthesiology.* **2021**;134(5):774–783. doi: [10.1097/ALN.0000000000003733](https://doi.org/10.1097/ALN.0000000000003733)
- [22] Chandel S, Khan M, Singh N, et al. The effect of sodium bicarbonate oral rinse on salivary pH and oral microflora: a prospective cohort study. *Natl J Maxillofac Surg.* **2017**;8(2):106–109. doi: [10.4103/njms.NJMS_36_17](https://doi.org/10.4103/njms.NJMS_36_17)
- [23] Drake D. Antibacterial activity of baking soda. *Compend Contin Educ Dent Suppl.* **1996**;17(19):S17–21.
- [24] Letscher-Bru V, Obszynski CM, Samsoen M, et al. Antifungal activity of sodium bicarbonate against fungal agents causing superficial infections. *Mycopathologia.* **2013**;175(1–2):153–158. doi: [10.1007/s11046-012-9583-2](https://doi.org/10.1007/s11046-012-9583-2)
- [25] Kesici U, Kesici S, Demirci M. Bicarbonate may alters bacterial susceptibility to antibiotics by targeting *Pseudomonas aeruginosa*, *Escherichia coli* and *staphylococcus aureus*. *J Contemp Med.* **2019**;9(3):245–248. doi: [10.16899/jcm.599259](https://doi.org/10.16899/jcm.599259)
- [26] Gawande PV, LoVetri K, Yakandawala N, et al. Antibiofilm activity of sodium bicarbonate, sodium metaperiodate and SDS combination against dental unit waterline-associated bacteria and yeast. *J Appl Microbiol.* **2008**;105(4):986–992. doi: [10.1111/j.1365-2672.2008.03823.x](https://doi.org/10.1111/j.1365-2672.2008.03823.x)
- [27] Corral LG, Post LS, Montville TJ. Antimicrobial activity of sodium bicarbonate: a research note. *J Food Sci.* **1988**;53(3):981–982. doi: [10.1111/j.1365-2621.1988.tb09005.x](https://doi.org/10.1111/j.1365-2621.1988.tb09005.x)
- [28] Abdalla DA, El Badrawy M, Abou Elela M, et al. Effect of bronchoalveolar lavage with sodium bicarbonate on lower respiratory tract pathogens. *Chest.* **2016**;149 (4):149. doi: [10.1016/j.chest.2016.02.093](https://doi.org/10.1016/j.chest.2016.02.093)
- [29] Jaikumpun P, Ruksakiet K, Stercz B, et al. Antibacterial effects of bicarbonate in media modified to mimic cystic fibrosis sputum. *Int J Mol Sci.* **2020**;21(22):21 (22. doi: [10.3390/ijms21228614](https://doi.org/10.3390/ijms21228614)
- [30] Pratten J, Wiecek J, Mordan N, et al. Physical disruption of oral biofilms by sodium bicarbonate: an in vitro study. *Int J Dent Hyg.* **2016**;14(3):209–214. doi: [10.1111/idh.12162](https://doi.org/10.1111/idh.12162)
- [31] Montville TJ, Goldstein PK. Sodium bicarbonate reduces viability and alters aflatoxin distribution of *aspergillus parasiticus* in Czapek's agar. *Appl Environ Microbiol.* **1987**;53(10):2303–2307. doi: [10.1128/aem.53.10.2303-2307.1987](https://doi.org/10.1128/aem.53.10.2303-2307.1987)
- [32] Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. *Nature.* **2001**;414(6862):454–457. doi: [10.1038/35106587](https://doi.org/10.1038/35106587)
- [33] Lee PH, Ohtake T, Zaiou M, et al. Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection. *Proc Natl Acad Sci U S A.* **2005**;102(10):3750–3755. doi: [10.1073/pnas.0500268102](https://doi.org/10.1073/pnas.0500268102)
- [34] Zasloff M. Antimicrobial peptides in health and disease. *N Engl J Med.* **2002**;347(15):1199–1200. doi: [10.1056/NEJMe020106](https://doi.org/10.1056/NEJMe020106)
- [35] Farha MA, French S, Stokes JM, et al. Bicarbonate alters bacterial susceptibility to antibiotics by targeting the proton motive force. *ACS Infect Dis.* **2018**;4 (3):382–390. doi: [10.1021/acscinfecdis.7b00194](https://doi.org/10.1021/acscinfecdis.7b00194)
- [36] Farha MA, Brown ED. Unconventional screening approaches for antibiotic discovery. *Ann N Y Acad Sci.* **2015**;1354(1):54–66. doi: [10.1111/nyas.12803](https://doi.org/10.1111/nyas.12803)
- [37] Gutiérrez-Huante M, Martínez H, Bustamante VH, et al. Bicarbonate enhances the in vitro antibiotic activity of kanamycin in *Escherichia coli*. *Lett Appl Microbiol.* **2015**;60(5):440–446. doi: [10.1111/lam.12388](https://doi.org/10.1111/lam.12388)
- [38] Bakker EP, Mangerich WE. Interconversion of components of the bacterial proton motive force by electrogenic potassium transport. *J Bacteriol.* **1981**;147 (3):820–826. doi: [10.1128/jb.147.3.820-826.1981](https://doi.org/10.1128/jb.147.3.820-826.1981)
- [39] Yamaguchi A, Ohmori H, Kaneko-Ohdera M, et al. Delta pH-dependent accumulation of tetracycline in *Escherichia coli*. *Antimicrob Agents Chemother.* **1991**;35(1):53–56. doi: [10.1128/AAC.35.1.53](https://doi.org/10.1128/AAC.35.1.53)
- [40] Taber HW, Mueller JP, Miller PF, et al. Bacterial uptake of aminoglycoside antibiotics. *Microbiol Rev.* **1987**;51(4):439–457. doi: [10.1128/mr.51.4.439-457.1987](https://doi.org/10.1128/mr.51.4.439-457.1987)
- [41] Holland M, Bjanes E, Nizet V, et al. Bicarbonate modulates delafloxacin activity against MDR *staphylococcus aureus* and *Pseudomonas aeruginosa*. *J Antimicrob Chemother.* **2022**;77(2):433–442. doi: [10.1093/jac/dkab421](https://doi.org/10.1093/jac/dkab421)
- [42] Rose WE, Bienvenida AM, Xiong YQ, et al. Ability of bicarbonate supplementation to sensitize selected methicillin-resistant *staphylococcus aureus* strains to β -lactam antibiotics in an ex vivo simulated endocardial vegetation Model. *Antimicrob Agents Chemother.* **2020**;64(3). doi: [10.1128/AAC.02072-19](https://doi.org/10.1128/AAC.02072-19)
- [43] Gutiérrez-Huante M, Martínez-Duncker ME, Saucedo E, et al. The antibiotics potentiator bicarbonate causes upregulation of tryptophanase and iron acquisition proteins in *Escherichia coli*. *Lett Appl Microbiol.* **2019**;68(1):87–95. doi: [10.1111/lam.13092](https://doi.org/10.1111/lam.13092)
- [44] Ersoy SC, Heithoff DM, Barnes L, et al. Correcting a fundamental flaw in the paradigm for antimicrobial susceptibility testing. *EBioMedicine.* **2017**;20:173–181. doi: [10.1016/j.ebiom.2017.05.026](https://doi.org/10.1016/j.ebiom.2017.05.026)

- [45] Ersoy SC, Abdelhady W, Li L, et al. Bicarbonate resensitization of methicillin-resistant staphylococcus aureus to β -lactam antibiotics. *Antimicrob Agents Chemother.* 2019;63(7):63(7. doi: [10.1128/AAC.00496-19](https://doi.org/10.1128/AAC.00496-19)
- [46] Ersoy SC, Hanson BM, Proctor RA, et al. Impact of bicarbonate- β -lactam exposures on methicillin-resistant staphylococcus aureus (MRSA) gene expression in bicarbonate- β -lactam-Responsive vs. Non-Responsive strains. *Genes (Basel).* 2021;12(11):1650. doi: [10.3390/genes12111650](https://doi.org/10.3390/genes12111650)
- [47] Ersoy SC, Chan LC, Yeaman MR, et al. Impacts of NaHCO₃ on β -lactam binding to PBP2a protein variants associated with the NaHCO₃-responsive versus NaHCO₃-non-responsive phenotypes. *Antibiotics (Basel).* 2022;11(4):11(4. doi: [10.3390/antibiotics11040462](https://doi.org/10.3390/antibiotics11040462)
- [48] Saleh MM, Yousef N, Shafik SM, et al. Attenuating the virulence of the resistant superbug Staphylococcus aureus bacteria isolated from neonatal sepsis by ascorbic acid, dexamethasone, and sodium bicarbonate. *BMC Microbiol.* 2022;22(1):268. doi: [10.1186/s12866-022-02684-x](https://doi.org/10.1186/s12866-022-02684-x)
- [49] Ersoy SC, Chambers HF, Proctor RA, et al. Impact of bicarbonate on PBP2a production, maturation, and functionality in methicillin-resistant Staphylococcus aureus (MRSA). *Antimicrob Agents Chemother.* 2023;65(5):65(5. doi: [10.1128/AAC.02621-20](https://doi.org/10.1128/AAC.02621-20)
- [50] Ersoy SC, Gonçalves B, Cavaco G, et al. Influence of sodium bicarbonate on Wall Teichoic acid synthesis and β -lactam sensitization in NaHCO₃-responsive and nonresponsive methicillin-resistant staphylococcus aureus. *Microbiol Spectr.* 2022;10(6):e0342222. doi: [10.1128/spectrum.03422-22](https://doi.org/10.1128/spectrum.03422-22)
- [51] Abe H, Tatsuno I, Tobe T, et al. Bicarbonate ion stimulates the expression of locus of enterocyte effacement-encoded genes in enterohemorrhagic Escherichia coli O157: H7. *Infect Immun.* 2002;70(7):3500–3509. doi: [10.1128/IAI.70.7.3500-3509.2002](https://doi.org/10.1128/IAI.70.7.3500-3509.2002)
- [52] Morgan JK, Carroll RK, Harro CM, et al. Global regulator of virulence a (GrvA) coordinates expression of discrete pathogenic mechanisms in enterohemorrhagic Escherichia coli through interactions with GadW-GadE. *J Bacteriol.* 2016;198(3):394–409. doi: [10.1128/JB.00556-15](https://doi.org/10.1128/JB.00556-15)
- [53] Morgan JK, Vendura KW, Stevens SM, et al. RcsB determines the locus of enterocyte effacement (LEE) expression and adherence phenotype of Escherichia coli O157: H7 spinach outbreak strain TW14359 and coordinates bicarbonate-dependent LEE activation with repression of motility. *Microbiol (Read).* 2013;159(Pt 11):2342–2353. doi: [10.1099/mic.0.070201-0](https://doi.org/10.1099/mic.0.070201-0)
- [54] Beyhan S, Tischler AD, Camilli A, et al. Differences in gene expression between the classical and El tor biotypes of Vibrio cholerae O1. *Infect Immun.* 2006;74(6):3633–3642. doi: [10.1128/IAI.01750-05](https://doi.org/10.1128/IAI.01750-05)
- [55] Iwanaga M, Yamamoto K. New medium for the production of cholera toxin by vibrio cholerae O1 biotype El Tor. *J Clin Microbiol.* 1985;22(3):405–408. doi: [10.1128/jcm.22.3.405-408.1985](https://doi.org/10.1128/jcm.22.3.405-408.1985)
- [56] Kotiranta A, Lounatmaa K, Haapasalo M. Epidemiology and pathogenesis of Bacillus cereus infections. *Microbes Infect.* 2000;2(2):189–198. doi: [10.1016/S1286-4579\(00\)00269-0](https://doi.org/10.1016/S1286-4579(00)00269-0)
- [57] Shimoyama Y, Umegaki O, Ooi Y, et al. Bacillus cereus pneumonia in an immunocompetent patient: a case report. *JA Clin Rep.* 2017;3(1):25. doi: [10.1186/s40981-017-0096-3](https://doi.org/10.1186/s40981-017-0096-3)
- [58] Helgason E, Økstad OA, Caugant DA, et al. Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis — one species on the basis of genetic evidence. *Appl Environ Microbiol.* 2000;66(6):2627–2630. doi: [10.1128/AEM.66.6.2627-2630.2000](https://doi.org/10.1128/AEM.66.6.2627-2630.2000)
- [59] Sirard JC, Mock M, Fouet A. The three bacillus anthracis toxin genes are coordinately regulated by bicarbonate and temperature. *J Bacteriol.* 1994;176(16):5188–5192. doi: [10.1128/jb.176.16.5188-5192.1994](https://doi.org/10.1128/jb.176.16.5188-5192.1994)
- [60] Casey JR. Why bicarbonate? This paper is one of a selection of papers published in this special issue, entitled CSBMCB — membrane proteins in health and disease. *Biochem Cell Biol.* 2006;84(6):930–939. doi: [10.1139/o06-184](https://doi.org/10.1139/o06-184)
- [61] Dai Z, Koehler TM. Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO₂/bicarbonate, affects AtxA synthesis. *Infect Immun.* 1997;65(7):2576–2582. doi: [10.1128/iai.65.7.2576-2582.1997](https://doi.org/10.1128/iai.65.7.2576-2582.1997)
- [62] Jang J, Cho M, Chun J-H, et al. The poly- γ -D-glutamic acid capsule of bacillus anthracis enhances lethal toxin activity. *Infect Immun.* 2011;79(9):3846–3854. doi: [10.1128/IAI.01145-10](https://doi.org/10.1128/IAI.01145-10)
- [63] Drysdale M, Bourgogne A, Koehler TM. Transcriptional analysis of the bacillus anthracis capsule regulators. *J Bacteriol.* 2005;187(15):5108–5114. doi: [10.1128/JB.187.15.5108-5114.2005](https://doi.org/10.1128/JB.187.15.5108-5114.2005)
- [64] Uchida I, Makino S-I, Sekizaki T, et al. Cross-talk to the genes for bacillus anthracis capsule synthesis by atxA, the gene encoding the trans-activator of anthrax toxin synthesis. *Mol Microbiol.* 1997;23(6):1229–1240. doi: [10.1046/j.1365-2958.1997.3041667.x](https://doi.org/10.1046/j.1365-2958.1997.3041667.x)
- [65] Koehler TM, Dai Z, Kaufman-Yarbray M. Regulation of the bacillus anthracis protective antigen gene: CO₂ and a trans-acting element activate transcription from one of two promoters. *J Bacteriol.* 1994;176(3):586–595. doi: [10.1128/jb.176.3.586-595.1994](https://doi.org/10.1128/jb.176.3.586-595.1994)
- [66] Passalacqua KD, Varadarajan A, Byrd B, et al. Comparative transcriptional profiling of Bacillus cereus sensu lato strains during growth in CO₂-bicarbonate and aerobic atmospheres. *PLoS One.* 2009;4(3):e4904. doi: [10.1371/journal.pone.0004904](https://doi.org/10.1371/journal.pone.0004904)
- [67] Scarff JM, Raynor MJ, Seldina YI, et al. The roles of AtxA orthologs in virulence of anthrax-like Bacillus cereus G9241. *Mol Microbiol.* 2016;102(4):545–561. doi: [10.1111/mmi.13478](https://doi.org/10.1111/mmi.13478)
- [68] Collins JW, Keeney KM, Crepin VF, et al. Citrobacter rodentium: infection, inflammation and the microbiota. *Nat Rev Microbiol.* 2014;12(9):612–623. doi: [10.1038/nrmicro3315](https://doi.org/10.1038/nrmicro3315)
- [69] Bourgogne A, Thomson LC, Murray BE. Bicarbonate enhances expression of the endocarditis and biofilm associated pilus locus, ebpR-ebpABC, in Enterococcus faecalis. *BMC Microbiol.* 2010;10(1):17. doi: [10.1186/1471-2180-10-17](https://doi.org/10.1186/1471-2180-10-17)

- [70] Bourgogne A, Singh KV, Fox KA, et al. EbpR is important for biofilm formation by activating expression of the endocarditis and biofilm-associated pilus operon (ebpABC) of *Enterococcus faecalis* OG1RF. *J Bacteriol.* **2007**;189(17):6490–6493. doi: [10.1128/JB.00594-07](https://doi.org/10.1128/JB.00594-07)
- [71] Koehler TM. *Bacillus anthracis* genetics and virulence gene regulation. *Curr Top Microbiol Immunol.* **2002**;271:143–164.
- [72] Mogensen EG, Janbon G, Chaloupka J, et al. *Cryptococcus neoformans* senses CO₂ through the carbonic anhydrase Can2 and the adenylyl cyclase Cac1. *Eukaryot Cell.* **2006**;5(1):103–111. doi: [10.1128/EC.5.1.103-111.2006](https://doi.org/10.1128/EC.5.1.103-111.2006)
- [73] Rose SJ, Bermudez LE, Kaufmann SHE. Identification of bicarbonate as a trigger and genes involved with extracellular DNA export in mycobacterial biofilms. *MBio.* **2016**;7(6). doi: [10.1128/mBio.01597-16](https://doi.org/10.1128/mBio.01597-16)
- [74] Johnson BK, Colvin CJ, Needle DB, et al. The carbonic anhydrase inhibitor ethoxzolamide inhibits the mycobacterium tuberculosis PhoPR regulon and *esx-1* secretion and attenuates virulence. *Antimicrob Agents Chemother.* **2015**;59(8):4436–4445. doi: [10.1128/AAC.00719-15](https://doi.org/10.1128/AAC.00719-15)
- [75] Aspatwar A, Hammarén M, Koskinen S, et al. β -carbonic anhydrase inhibitor dithiocarbamate Fc14–584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. *J Enzyme Inhib Med Chem.* **2017**;32(1):832–840. doi: [10.1080/14756366.2017.1332056](https://doi.org/10.1080/14756366.2017.1332056)
- [76] Siew R, Ou T-L, Dahesh S, et al. Bicarbonate effects on antibacterial immunity and mucus glycobiology in the cystic fibrosis lung: a review with selected experimental observations. *Infect Microb Dis.* **2022**;4(3):103–110. doi: [10.1097/IM9.0000000000000101](https://doi.org/10.1097/IM9.0000000000000101)
- [77] Abbas G, Ahmad F, Saeed M, et al. Effect of dietary inclusion of sodium bicarbonate on digestibility of nutrients and immune response in caged layers during the summer. *B J Poul Sci.* **2019**;21(2):21(2). doi: [10.1590/1806-9061-2018-0915](https://doi.org/10.1590/1806-9061-2018-0915)
- [78] Hewawaduge C, Senevirathne A, Lee JH. Enhancement of host infectivity, immunity, and protective efficacy by addition of sodium bicarbonate antacid to oral vaccine formulation of live attenuated salmonella secreting *Brucella* antigens. *Microb Pathog.* **2020**;138:103857. doi: [10.1016/j.micpath.2019.103857](https://doi.org/10.1016/j.micpath.2019.103857)
- [79] Strowitzki MJ, Nelson R, Garcia MP, et al. Carbon dioxide sensing by immune cells occurs through carbonic anhydrase 2-dependent changes in intracellular pH. *J Immunol.* **2022**;208(10):2363–2375. doi: [10.4049/jimmunol.2100665](https://doi.org/10.4049/jimmunol.2100665)
- [80] Helenius IT, Krupinski T, Turnbull DW, et al. Elevated CO₂ suppresses specific drosophila innate immune responses and resistance to bacterial infection. *Proc Natl Acad Sci U S A.* **2009**;106(44):18710–18715. doi: [10.1073/pnas.0905925106](https://doi.org/10.1073/pnas.0905925106)
- [81] Schneberger D, Pandher U, Thompson B, et al. Effects of elevated CO₂ levels on lung immune response to organic dust and lipopolysaccharide. *Respir Res.* **2021**;22(1):104. doi: [10.1186/s12931-021-01700-4](https://doi.org/10.1186/s12931-021-01700-4)
- [82] Dechow S, Goyal R, Johnson BJ, et al. Carbon dioxide regulates mycobacterium tuberculosis PhoPR signaling and virulence. *bioRxiv.* **2022**.
- [83] An Y, Ni R, Zhuang L, et al. Tuberculosis vaccines and therapeutic drug: challenges and future directions. *Mol Biomed.* **2025**;6(1):4. doi: [10.1186/s43556-024-00243-6](https://doi.org/10.1186/s43556-024-00243-6)
- [84] Parkkinen J, Bhowmik R., Tolvanen, M., Carta, F., Supuran, C.T., Parkkila, S. and Aspatwar, A. Mycobacterial β -carbonic anhydrases: molecular biology, role in the pathogenesis of tuberculosis and inhibition studies. *Enzymes.* **2024**;55:343–381.
- [85] Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? *Front Pharmacol.* **2011**;2:34. doi: [10.3389/fphar.2011.00034](https://doi.org/10.3389/fphar.2011.00034)
- [86] Chilambi GS, Wang Y-H, Wallace NR, et al. Carbonic anhydrase inhibition as a target for antibiotic synergy in enterococci. *Microbiol Spectr.* **2023**;11(4):e0396322. doi: [10.1128/spectrum.03963-22](https://doi.org/10.1128/spectrum.03963-22)
- [87] Supuran CT. Novel carbonic anhydrase inhibitors for the treatment of *Helicobacter pylori* infection. *Expert Opin Investig Drugs.* **2024**;33(5):523–532. doi: [10.1080/13543784.2024.2334714](https://doi.org/10.1080/13543784.2024.2334714)
- [88] Stähler FN, Ganter L, Lederer K, et al. Mutational analysis of the *Helicobacter pylori* carbonic anhydrases. *FEMS Immunol Med Microbiol.* **2005**;44(2):183–189. doi: [10.1016/j.femsim.2004.10.021](https://doi.org/10.1016/j.femsim.2004.10.021)
- [89] Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov.* **2008**;7(2):168–181. doi: [10.1038/nrd2467](https://doi.org/10.1038/nrd2467)
- [90] Nocentini A, Capasso C, Supuran CT. Carbonic anhydrase inhibitors as novel Antibacterials in the era of antibiotic resistance: where are we Now? *Antibiotics (Basel).* **2023**;12(1):12(1). doi: [10.3390/antibiotics12010142](https://doi.org/10.3390/antibiotics12010142)
- [91] Aspatwar A, Hammaren M, Parikka M, et al. In vitro inhibition of mycobacterium tuberculosis β -carbonic anhydrase 3 with mono- and dithiocarbamates and evaluation of their toxicity using zebrafish developing embryos. *J Enzyme Inhib Med Chem.* **2020**;35(1):65–71. doi: [10.1080/14756366.2019.1683007](https://doi.org/10.1080/14756366.2019.1683007)
- [92] Bhowmik R, Vyas A, Manaihiya B, et al. Navigating bioactivity space in anti-tubercular drug discovery through the deployment of advanced machine learning models and cheminformatics tools: a molecular modeling based retrospective study. *Front Pharmacol.* **2023**;14:1265573. doi: [10.3389/fphar.2023.1265573](https://doi.org/10.3389/fphar.2023.1265573)